Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Aridis Pharmaceuticals, Inc is a biotechnology business based in the US. Aridis Pharmaceuticals shares (ARDS) are listed on the NASDAQ and all prices are listed in US Dollars. Aridis Pharmaceuticals employs 25 staff and has a trailing 12-month revenue of around USD$1 million.
|Latest market close||USD$7.3|
|52-week range||USD$3.8 - USD$10|
|50-day moving average||USD$6.8503|
|200-day moving average||USD$6.9661|
|Wall St. target price||USD$17.2|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-4.187|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-07)||21.67%|
|1 month (2020-12-17)||5.95%|
|3 months (2020-10-15)||-7.01%|
|6 months (2020-07-15)||10.11%|
|1 year (2020-01-15)||-3.69%|
|2 years (2019-01-15)||-17.05%|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
Valuing Aridis Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aridis Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aridis Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Aridis Pharmaceuticals shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$1 million|
|Gross profit TTM||USD$-23,061,000|
|Return on assets TTM||-59.89%|
|Return on equity TTM||0%|
|Market capitalisation||USD$66 million|
TTM: trailing 12 months
There are currently 8,248 Aridis Pharmaceuticals shares held short by investors – that's known as Aridis Pharmaceuticals's "short interest". This figure is 28.4% down from 11,526 last month.
There are a few different ways that this level of interest in shorting Aridis Pharmaceuticals shares can be evaluated.
Aridis Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Aridis Pharmaceuticals shares currently shorted divided by the average quantity of Aridis Pharmaceuticals shares traded daily (recently around 19181.395348837). Aridis Pharmaceuticals's SIR currently stands at 0.43. In other words for every 100,000 Aridis Pharmaceuticals shares traded daily on the market, roughly 430 shares are currently held short.
However Aridis Pharmaceuticals's short interest can also be evaluated against the total number of Aridis Pharmaceuticals shares, or, against the total number of tradable Aridis Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Aridis Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Aridis Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0007% of the tradable shares (for every 100,000 tradable Aridis Pharmaceuticals shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Aridis Pharmaceuticals.
Find out more about how you can short Aridis Pharmaceuticals stock.
We're not expecting Aridis Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Aridis Pharmaceuticals's shares have ranged in value from as little as $3.8 up to $10. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aridis Pharmaceuticals's is 0.2107. This would suggest that Aridis Pharmaceuticals's shares are less volatile than average (for this exchange).
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase II clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients and acute pneumonia in HAP and VAP patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in San Jose, California.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.